DE | Accessible presentation
Translations are powered by AI

These Munich startups are ripe for investment

Which startups have the best prospects of successfully completing a financing round soon? We take a look into the crystal ball and introduce you to five companies that are ripe for investment.

August 22, 2024 4 min reading time

Mbiomics focuses on developing the first generation of effective live bacterial therapeutics. The company uses its proprietary profiling platform and computational technologies to generate high-resolution precision data on microbiota modulation. The technology is intended to enable a better understanding of the interactions between the gut microbiome and the host, thereby Mbiomics aims to develop microbial consortia that can be delivered to patients as precision therapies. The Munich-based biotech company aims to revolutionize the treatment of a broad spectrum of diseases – from cancer to inflammatory bowel disease. Mbiomics' last financing – a €13 million Series A – was completed in early 2023. The dealroom signal is at 87 points, with 100 points in the timing segment. (Image: Wirestock / Freepik)
read more ↓